Abstract
Dupilumab was approved in the EU in 2017 for the treatment of moderate-to-severe atopic dermatitis (AD). The good therapeutic response described in clinical trials has yet to be confirmed in everyday clinical care settings. The German registry TREATgermany is the largest European registry for patients with moderate to severe AD with more than 1,400 patients currently (May 2022) enrolled. Patients are prospectively monitored and clinical course, treatment, and patient-reported outcomes (PROMs) are documented.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
